Type: clinical_evidence
Status: Results Published (NEJM 2025)
Developer: Eli Lilly
The SUMMIT trial demonstrated that tirzepatide (dual GIP/GLP-1 RA) significantly reduced the composite endpoint of cardiovascular death and worsening heart failure events by 38% in patients with HFpEF and T2D/obesity. Published in NEJM (2025). Establishes a new treatment paradigm: addressing metabolic root causes of HFpEF.
Dual GIP/GLP-1 receptor agonism reduces body weight, visceral adiposity, and systemic inflammation. In HFpEF, this reduces pericardial fat, improves diastolic function, lowers filling pressures, and enhances exercise capacity through metabolic remodeling rather than traditional diuretic or neurohormonal pathways.
Year: 2025